Matthew T Seymour

Matthew T Seymour

UNVERIFIED PROFILE

Are you Matthew T Seymour?   Register this Author

Register author
Matthew T Seymour

Matthew T Seymour

Publications by authors named "Matthew T Seymour"

Are you Matthew T Seymour?   Register this Author

38Publications

1170Reads

42Profile Views

Choosing the right strategy based on individualized treatment effect predictions: combination versus sequential chemotherapy in patients with metastatic colorectal cancer.

Acta Oncol 2019 Mar 18;58(3):326-333. Epub 2019 Jan 18.

h Department of Medical Oncology , University Medical Center Utrecht, Utrecht University , Utrecht , The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/0284186X.2018.1564840DOI Listing
March 2019

Use of Gene Expression Profiles to Distinguish Molecular Subtypes in Colorectal Cancer: Progression Toward Primetime.

J Natl Cancer Inst 2017 Jul;109(7)

Institute of Cancer and Pathology, University of Leeds, Leeds, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djx019DOI Listing
July 2017

Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en Cancérologie Digestive Database.

J Clin Oncol 2017 Jun 17;35(17):1929-1937. Epub 2017 Apr 17.

Lindsay A. Renfro, Axel Grothey, and Daniel J. Sargent, Mayo Clinic, Rochester, MN; Richard M. Goldberg, The Ohio State University, Columbus, OH; Alberto Sobrero, Ospedale San Martino, Genoa; Alfredo Falcone, University Hospital of Pisa, Pisa, Italy; Richard Adams, Cardiff University, Cardiff; Matthew T. Seymour, St James's Hospital and University of Leeds, Leeds, United Kingdom; Volker Heinemann, University of Munich, Munich; Hans-Joachim Schmoll, University Clinic Halle (Saale), Halle; Rainer Porschen, Klinikum Bremen-Ost Klinik für Innere Medizin, Bremen; Carsten Bokemeyer, University Hospital, Hamburg-Eppendorf, Germany; Jean-Yves Douillard, Centre René Gauducheau, Nantes; Christophe Tournigand, University of Paris Est Creteil; Christophe Tournigand, Assistance Hopitaux Publique de Paris Henri-Mondor Hospital, Créteil; Benoist Chibaudel and Aimery de Gramont, Franco-British Institute, Levallois-Perret, France; Herbert Hurwitz, Duke University Medical Center, Durham, NC; Charles S. Fuchs; Dana-Farber Cancer Institute, Boston, MA; Eduardo Diaz-Rubio, Hospital Clínico San Carlos, Universidad Complutense, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos, Madrid, Spain; Paulo M. Hoff, Hospital Sírio-Libanês and University of São Paulo, São Paulo, Brazil; Fairooz F. Kabbinavar and J. Randolph Hecht, David Geffen School of Medicine at University of California at Los Angeles, Los Angeles, CA; Niall C. Tebbutt, Austin Health, Heidelberg, Victoria, Australia; Cornelis J.A. Punt, University of Amsterdam, Amsterdam, the Netherlands; John Souglakos, University of Crete, Heraklion, Greece; Eric Van Cutsem, University Hospital Leuven, Leuven, Belgium; and Leonard Saltz, Memorial Sloan Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.71.5771DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5466009PMC
June 2017

Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database.

J Clin Oncol 2016 Jan 26;34(2):144-50. Epub 2015 Oct 26.

Lindsay A. Renfro and Daniel J. Sargent, Mayo Clinic, Rochester, MN; Fotios Loupakis and Alfredo Falcone, Azienda Ospedaliero-Universitaria Pisana and Università di Pisa, Pisa, Italy; Richard Adams, Cardiff University, Cardiff; Matthew T. Seymour, St James's Hospital and University of Leeds, Leeds, United Kingdom; Volker Heinemann, University of Munich, Munich; Hans-Joachim Schmoll, University Clinic Halle (Saale), Halle; Rainer Porschen, Klinikum Bremen-Ost Klinik für Innere Medizin, Bremen; Carsten Bokemeyer, University Hospital Cancer Center, University Hospital, Hamburg-Eppendorf, Germany; Jean-Yves Douillard, Institut de Cancerologie, Centre René Gauducheau, Nantes; Christophe Tournigand, University of Paris Est Creteil, Henri-Mondor Hospital, Créteil; Benoist Chibaudel and Aimery de Gramont, Franco-British Institute, Levallois-Perret, France; Herbert Hurwitz, Duke University Medical Center, Durham, NC; Charles S. Fuchs, Dana-Farber Cancer Institute Boston, MA; Eduardo Diaz-Rubio, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos, Madrid, Spain; Niall C. Tebbutt, Austin Health, Heidelberg, Victoria, Australia; Cornelis J.A. Punt, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands; J. Randolph Hecht, David Geffen School of Medicine at the University of California at Los Angeles; Heinz-Josef Lenz, University of Southern California/Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, CA; Eric Van Cutsem, University Hospital Leuven, Leuven, Belgium; Richard M. Goldberg, Ohio State University, Columbus, OH; and Leonard B. Saltz, Memorial Sloan-Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.61.6441DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070548PMC
January 2016

Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system database.

J Clin Oncol 2015 Jan 10;33(1):22-8. Epub 2014 Nov 10.

Qian Shi, Axel Grothey, and Daniel J. Sargent, Mayo Clinic, Rochester, MN; Aimery de Gramont and Benoist Chibaudel, Hospital Saint Antoine; Christophe Tournigand, Université Paris Est Créteil, Paris; Jean-Yves Douillard, Institute of Cancer Research in Western, St Herblain, France; John Zalcberg, Monash University; Niall C. Tebbutt, Austin Health, Melbourne, Victoria, Australia; Hans-Joachim Schmoll, Martin-Luther University, Halle; Rainer Porschen, Klinikum Bremen-Ost, Bremen; Volker Heinemann, University of Munich, München; Carsten Bokemeyer, University Hospital, Hamburg-Eppendorf, Germany; Matthew T. Seymour, Cancer Research UK Clincal Center, Leeds; Richard Adams, Cardiff University, Cardiff, United Kingdom; Leonard Saltz, Memorial Sloan-Kettering Cancer Center, New York, NY; Richard M. Goldberg, Ohio State University, Columbus, OH; Cornelis J.A. Punt, Academic Medical Center, Amsterdam, the Netherlands; Paulo M. Hoff, Hospital Sírio-Libanês, Sao Paulo, Brazil; Joel Randolph Hecht and Fairooz F. Kabbinavar, University of California at Los Angeles, Los Angeles, CA; Herbert Hurwitz, Duke University, Durham, NC; Eduardo Díaz-Rubio, Hospital Clinico San Carlos, Madrid, Spain; Charles Fuchs, Dana-Farber Cancer Institute, Boston, MA; John Souglakos, University of Crete, Heraklion, Greece; Alfredo Falcone, University of Pisa, Pisa, Italy; Eric Van Cutsem, University Hospital Gasthuisberg, Leuven; and Marc Buyse, International Drug Development Institute, Louvain-la-Neuve, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.56.5887DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4482837PMC
January 2015

Adjuvant bevacizumab in colon cancer: where did we go wrong?

Lancet Oncol 2012 Dec 16;13(12):1176-7. Epub 2012 Nov 16.

Section of Oncology and Clinical Research, Leeds Institute of Molecular Medicine, University of Leeds, Leeds LS9 7TF, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(12)70521-1DOI Listing
December 2012

Balancing the efficacy and toxicity of chemotherapy in colorectal cancer.

Ther Adv Med Oncol 2011 Jan;3(1):43-52

Consultant, Department of Medical Oncology, The Christie NHS Foundation Trust, Wilmslow Road, Withington, Manchester M20 4BX, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1758834010388342DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3126034PMC
January 2011

KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial.

J Clin Oncol 2009 Dec 2;27(35):5931-7. Epub 2009 Nov 2.

Leeds Institute of Molecular Medicine, St. James's Institute of Oncology, Cancer Research UK Genomic Services, University of Leeds, Leeds, UK.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2009.22.4295
Publisher Site
http://dx.doi.org/10.1200/JCO.2009.22.4295DOI Listing
December 2009

Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial.

J Clin Oncol 2009 Nov 26;27(33):5519-28. Epub 2009 Oct 26.

Oncology & Clinical Research and Pathology & Tumour Biology Sections, Leeds Institute of Molecular Medicine, University of Leeds, Leeds, United Kingdom.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/27/33/5519.full.pdf
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2008.21.6283
Publisher Site
http://dx.doi.org/10.1200/JCO.2008.21.6283DOI Listing
November 2009

The CAIRO and FOCUS studies: which lesson is to be learned?

Oncologist 2009 Feb;14(2):192-3; author reply 194-6

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2008-0247DOI Listing
February 2009

Severe sequence-specific toxicity when capecitabine is given after Fluorouracil and leucovorin.

J Clin Oncol 2008 Jul;26(20):3411-7

Cancer Research UK Centre, St James's Institute of Oncology, St James's University Hospital, Leeds LS9 7TF, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2007.15.9426DOI Listing
July 2008

CAIRO and FOCUS.

Lancet 2007 Dec;370(9603):1904-5; author reply 1905

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0140-6736(07)61807-8DOI Listing
December 2007

Molecular markers of chemotherapeutic response and toxicity in colorectal cancer.

Expert Rev Anticancer Ther 2007 Apr;7(4):489-501

University of Leeds, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/14737140.7.4.489DOI Listing
April 2007

Lack of pharmacokinetic interaction between 5-fluorouracil and oxaliplatin.

Clin Pharmacol Ther 2004 Jul;76(1):45-54

Department of Medical Oncology, St Bartholomew's Hospital, London, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clpt.2004.03.008DOI Listing
July 2004

Oxaliplatin: bimonthly, biweekly, or semimonthly? No, fortnightly!

J Clin Oncol 2002 Sep;20(17):3753

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2002.99.145DOI Listing
September 2002

Prediction of the response of colorectal cancer to systemic therapy.

Lancet Oncol 2002 Feb;3(2):75-82

Academic Department of Pathology, University of Leeds, UK.

View Article

Download full-text PDF

Source
February 2002